Last reviewed · How we verify
NCT02932202: WEIGHT
Women Eating With Interactive Tracking to Gain Healthily Through Term Pregnancy Trial
NA trial testing Longitudinal Nutritional Counseling in Obesity. Withdrawn.
17 May 2017
Quick facts
| Lead sponsor | Loyola University |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Start date | 8 July 2016 |
| Primary completion | 17 May 2017 |
| Estimated completion | 17 May 2017 |
Drugs / interventions tested
- Longitudinal Nutritional Counseling
- Standard Care — full drug profile →
Conditions studied
- Obesity — all drugs for Obesity →
- Pregnancy — all drugs for Pregnancy →
- Weight Gain — all drugs for Weight Gain →
Sponsor
Loyola University
Who can join
18 and older, female only, with Obesity or Pregnancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Obesity and excessive weight gain in pregnancy have significant associated maternal and fetal complications including gestational diabetes, large for gestational age infants, birth trauma, and stillbirth. The standard of care places the responsibility on the providers during prenatal visits to remind patients of their weight gain goals and provide appropriate counseling. The objective of this study is to evaluate a sustainable medical student-assisted longitudinal program of nutritional counseling and web based nutrition tracking for pregnant women on excessive weight gain during pregnancy and the effects on diet choices and fetal and maternal complications.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02932202
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other Loyola University trials
Trials by the same sponsor.
- NCT07517224 — Assessing the Effect of an Aerobic Exercise Program on Vascular Function in Women With Non-Metastatic Breast Cancer · NA · not yet recruiting
- NCT06486714 — Mechanical Alignment Versus Kinematic Alignment Total Knee Arthroplasty · NA · not yet recruiting
- NCT07216664 — Multisensory Early Oral Administration of Human Milk (M-MILK) for Very Preterm Infants · NA · recruiting
- NCT07226505 — Effects of Core Strengthening Exercises for Treating TMD · NA · not yet recruiting
- NCT06525701 — Surgeon Core-strengthening Program as a Modifier for Exertion Associated With Vaginal Surgery · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02932202 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Loyola University
- Last refreshed: 1 June 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02932202.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing